Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.…
Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call
Cardio Diagnostics Holdings (NASDAQ: CDIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 1.600 USD on 20 November 2026, down 58.5% over 52 weeks. Its 52-week range is 0.9700 USD to 7.910 USD: the price is 79.8% below the high and 64.9% above the low.
Its market capitalisation is 4.74M USD.
Cardio Diagnostics Holdings reports return on equity of -93.2% and revenue up 25.7% year over year.
It holds more cash than debt, a net cash position of 3.70M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 12 March 2027.